ArticleArchives of dermatological research2024
Update on skin cancer prevention modalities and screening protocols in solid organ transplant recipients: a scoping review.
Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A Narrative Review of the Factors Impacting Solid Organ Transplant Recipient Participation in Skin Cancer Screening.The Australasian journal of dermatology · 2026Review
- Chemoprevention in Skin Cancer: What Advice?Cancers · 2026Review
- Skin Cancers in People Living with Human Immunodeficiency Virus (HIV) Infection.Journal of clinical medicine · 2025Article
- Response Rate to the Intervention with Tirbanibulin 1% Ointment for Treating Actinic Keratoses in People Living with HIV Infection.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Solid organ transplant recipients (SOTRs) are at significantly increased risk for skin cancer, particularly due to lifelong immunosuppressant use. Despite this risk, standardized guidelines for skin cancer risk stratification and screening in SOTRs are lacking in the United States. This scoping review aims to summarize existing evidence on skin cancer prevention and screening protocols to inform the development of standardized guidelines. A systematic search was conducted using OVID, MEDLINE, and CINAHL Plus databases, focusing on English-language articles published between January 1, 2019, and February 12, 2023. The review included studies addressing skin cancer risk stratification, screening, and preventive therapies in adult SOTRs. Data extraction followed the JBI Manual for Evidence Synthesis PRISMA guidelines, with articles graded for quality using the Strength of Recommendation Taxonomy (SORT). Thirty-six articles were included in the review. The findings revealed that most studies focused on skin cancer screening protocols (36%) and chemoprevention treatments (31%) for SOTRs. The SUNTRAC tool, developed in 2019, emerged as a validated risk stratification model. Preventive strategies identified include systemic treatments like low-dose acitretin, capecitabine, niacinamide, and topical therapies such as 5-fluorouracil and photodynamic therapy. Preventive strategy strength of evidence was graded and summarized into a practical reference table. Patient education, particularly through electronic methods, was highlighted as essential for fostering photoprotective behaviors. The review highlights the need for standardized skin cancer screening and prevention guidelines for SOTRs, with the SUNTRAC tool providing a robust model for risk stratification. Future research should focus on validating the SUNTRAC tool across diverse populations, conducting randomized controlled trials on topical chemoprevention, and enhancing patient education, particularly among Skin of Color patients.
Indexed as
Identifiers
39589541What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.